RecruitingPhase 2NCT07420985

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

A Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of the Investigational Product Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Sponsor

Valenta Pharm JSC

Enrollment

300 participants

Start Date

Oct 24, 2025

Study Type

INTERVENTIONAL

Conditions

Influenza Acute Respiratory Viral Infection

Summary

The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ingavirin Forte, 90 mg + 10 mg, Capsules, a drug called Ingavirin Forte, 90 mg + 20 mg, Capsules, and others for people with acute respiratory viral infection and influenza. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIngavirin Forte, 90 mg + 5 mg, Capsules

90 mg + 5 mg, 1 capsule twice a day, for 5 days

DRUGIngavirin Forte, 90 mg + 10 mg, Capsules

90 mg + 10 mg, 1 capsule twice a day, for 5 days

DRUGIngavirin Forte, 90 mg + 20 mg, Capsules

90 mg + 20 mg,1 capsule twice a day, for 5 days

DRUGIngavirin, 90 mg, Capsules

90 mg, 1 capsule twice a day, for 5 days

DRUGPlacebo

1 capsule twice a day, for 5 days

Locations(11)

Regional Budgetary Healthcare Institution "Kuvaev Ivanovo Clinical Hospital"

Ivanovo, Russia

Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation

Kirov, Russia

"Medical and Diagnostic Center Veris" LLC

Kirov, Russia

State Budgetary Healthcare Institution of the City of Moscow "Consultative and Diagnostic Polyclinic № 121 of the Moscow City Department of Healthcare"

Moscow, Russia

Unimed-C Jsc

Moscow, Russia

"Professor's Clinic" LLC

Perm, Russia

"Aurora MedFort" LLC

Saint Petersburg, Russia

"Eosmed" LLC

Saint Petersburg, Russia

"OrCli Hospital" LLC

Saint Petersburg, Russia

Federal State Budgetary Educational Institution of Higher Education "National Research Ogarev Mordovia State University"

Saransk, Russia

"DNA Research Center" LLC

Saratov, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07420985

Related Trials

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

NCT047125391 location

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

NCT072295471 location

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(11)

Related Trials

BPL-1357 Against H1N1 Influenza Virus Challenge

pH1N1 Blinded Challenge Study

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.